Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders

Simply Wall St.02-01 05:45

Sanofi agreed to acquire Dynavax Technologies (NasdaqGS:DVAX) in a multi billion dollar deal. The transaction focuses on adding Dynavax's approved hepatitis B vaccine and its experimental shingles ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608003825?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-01 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608003825","market":"us","top_or_hot":-1,"title":"Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Sanofi agreed to acquire Dynavax Technologies (NasdaqGS:DVAX) in a multi billion dollar deal. The transaction focuses on adding Dynavax's approved hepatitis B vaccine and its experimental shingles ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/sanofi-buyout-of-dynavax-recasts-adult-vaccine-growth-for-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-01 05:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/sanofi-buyout-of-dynavax-recasts-adult-vaccine-growth-for-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi agreed to acquire Dynavax Technologies (NasdaqGS:DVAX) in a multi billion dollar deal. The transaction focuses on adding Dynavax's approved hepatitis B vaccine and its experimental shingles ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/sanofi-buyout-of-dynavax-recasts-adult-vaccine-growth-for-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德纳维制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/sanofi-buyout-of-dynavax-recasts-adult-vaccine-growth-for-sh","article_id":"2608003825","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/sanofi-buyout-of-dynavax-recasts-adult-vaccine-growth-for-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608003825","pubTimestamp":1769895926,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sanofi agreed to acquire Dynavax Technologies (NasdaqGS:DVAX) in a multi billion dollar deal.\nThe transaction focuses on adding Dynavax's approved hepatitis B vaccine and its experimental shingles vaccine to Sanofi's adult vaccines portfolio.\nThe deal is framed as an expansion of Sanofi's presence in adult immunizations.\n\nDynavax Technologies, known for its vaccine work including its hepatitis B product, sits at the intersection of adult immunization and broader infectious disease...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药","BK4139":"生物科技","BK4007":"制药","SNYNF":"Sanofi"},"translate_title":"赛诺菲收购Dynavax为股东重塑成人疫苗增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVAX":1.5,"SNYNF":1.5},"content_text":"Sanofi agreed to acquire Dynavax Technologies (NasdaqGS:DVAX) in a multi billion dollar deal. The transaction focuses on adding Dynavax's approved hepatitis B vaccine and its experimental shingles vaccine to Sanofi's adult vaccines portfolio. The deal is framed as an expansion of Sanofi's presence in adult immunizations.  Dynavax Technologies, known for its vaccine work including its hepatitis B product, sits at the intersection of adult immunization and broader infectious disease prevention. Large pharmaceutical groups have been active in vaccines as they look to build out portfolios in areas such as hepatitis, shingles, respiratory infections and other adult indications. This agreement places Dynavax's assets within a larger global commercial and development platform. For you as an investor, the acquisition raises questions around how Dynavax's products might be integrated, funded and prioritized within Sanofi's broader vaccine efforts. It also puts a spotlight on the role of adult vaccines in future product lineups, especially as healthcare systems continue to pay attention to preventable diseases in older and at risk populations. Stay updated on the most important news stories for Dynavax Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Dynavax Technologies. NasdaqGS:DVAX Earnings & Revenue Growth as at Jan 2026 How Dynavax Technologies stacks up against its biggest competitors For Dynavax shareholders, the agreed all cash takeout by Sanofi crystallizes the value of its hepatitis B franchise and early shingles program into a single transaction, rather than leaving those assets to be valued through future clinical and commercial milestones. The deal also effectively hands control of Dynavax's vaccine platform to a larger player in adult immunizations that already competes with names like GSK and Pfizer. AdvertisementHow this ties into the Dynavax Technologies Narrative Earlier bullish narratives around Dynavax focused on HEPLISAV B growth, the potential of the shingles candidate and broader use of its CpG 1018 adjuvant in government and partner programs, which together were seen as drivers of long term upside. The Sanofi acquisition channels those expectations into a negotiated cash value today, so the debate for you now shifts from long term compounding to whether the agreed price suitably reflects those earlier growth and diversification arguments. Risks and rewards for shareholders  Cash consideration provides certainty of value and removes execution risk around future clinical trials, reimbursement decisions and competitive responses from GSK or Pfizer. Integration into Sanofi's global commercial network could support wider use of Dynavax's vaccine technologies, which some investors may view as a validation of the underlying platform. Once the deal closes, you lose direct exposure to any upside if HEPLISAV B or the shingles vaccine outperform expectations inside Sanofi's broader portfolio. The transaction still needs shareholder and regulatory approvals, so there is some deal completion risk and timing uncertainty to keep in mind.  What to watch from here From here, the key things to watch are closing milestones, any competing interest that might emerge, and whether updated disclosures from Dynavax or Sanofi change how you think about the underlying vaccine assets. If you want to see how other investors are thinking about the trade off between taking the deal price and the long term story, you can check community narratives on Dynavax's dedicated page.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608003825","isCrawlerRequest":true}